Edward J. O'Brien, PhD

Group Leader, Computational Microbiome Sciences
Seres Therapeutics
Cambridge, Massachusetts, United States

Seres Therapeutics (Employee, Shareholder)

Presentation(s):

• 130 - Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

  On Demand